Results from the SWOG S1416 clinical trial show that adding veliparib
to chemotherapy can significantly extend progression-free survival
(PFS) times in patients with triple-negative breast cancer (TNBC) that
has a "BRCA-like" phenotype.
Veliparib belongs to a class of drugs known as PARP inhibitors. PARP
inhibitors have been shown to be effective in treating breast cancer
with germline mutations in the BRCA1 or BRCA2 gene. But this is the first trial to demonstrate a PARP inhibitor benefit in breast cancer that is not BRCA1/2-mutated but is BRCA-like based on the presence of other changes that similarly affect cells' DNA repair abilities.
Results from the trial, which was led by researchers from SWOG Cancer
Research Network, a cancer clinical trials group funded by the National
Cancer Institute (NCI), are published in Lancet Oncology.
Priyanka Sharma, MD, a SWOG investigator who is professor of medicine
at the University of Kansas Medical Center was co-lead author on the
paper with Eve Rodler, MD, associate professor of medicine at University
of California, Davis.
SWOG 1416 is the first trial to report benefit of a PARP inhibitor in
metastatic TNBC with a BRCA-like phenotype in absence of germline
mutations in BRCA1 or BRCA2 genes. BRCA-like phenotype
is noted in 40 to 50 percent of triple negative breast cancers, making
these findings and BRCA-like classification relevant for a substantial
proportion of patients with TNBC."
Priyanka Sharma, MD, a SWOG investigator
Germline mutations in the BRCA1 or BRCA2 gene
increase the number of errors made in the DNA repair process in cells.
Poly (ADP-ribose) polymerase – or PARP – is an enzyme in cells that
helps repair damaged DNA, and drugs that inhibit PARP activity have been
shown to be effective in treating breast cancer occurring in the
setting of germline BRCA1 or BRCA2 mutations.
Many triple negative tumors, however, have no germline mutations in
these genes but do have other alterations that negatively affect the DNA
repair process in ways similar to the effects of germline BRCA1/2 mutations. The S1416 team asked whether these BRCA-like cancers could also be treated effectively with PARP inhibitors. . . .
. . ."While these results are not immediately practice changing, since
veliparib is not FDA approved," Sharma said, "S1416 findings open new
clinical trial directions by extending the patient population that could
benefit from PARPi therapy. With demonstration of https://www.news-medical.net/health/What-Does-Efficacy-Mean.aspx" rel="nofollow - efficacy
in BRCA-like phenotype TNBC, S1416 results provide a basis for
expanding the therapeutic role of PARP inhibitors (e.g., veliparib)
beyond germline BRCA mutation in breast cancer."
https://www.news-medical.net/news/20230131/Adding-veliparib-to-chemotherapy-can-extend-progression-free-survival-in-patients-with-e2809cBRCA-likee2809d-breast-cancer.aspx" rel="nofollow - https://www.news-medical.net/news/20230131/Adding-veliparib-to-chemotherapy-can-extend-progression-free-survival-in-patients-with-e2809cBRCA-likee2809d-breast-cancer.aspx